INSY has been the topic of a number of other research reports. Zacks Investment Research downgraded Insys Therapeutics from a buy rating to a hold rating in a research report on Wednesday, October 25th. Jefferies Group LLC cut their price objective on Insys Therapeutics from $14.00 to $11.00 and set a buy rating on the stock in a report on Friday, November 3rd. Royal Bank Of Canada reiterated an outperform rating and issued a $14.00 price objective on shares of Insys Therapeutics in a report on Wednesday, October 11th. TheStreet downgraded Insys Therapeutics from a c- rating to a d+ rating in a report on Monday, August 21st. Finally, BidaskClub downgraded Insys Therapeutics from a sell rating to a strong sell rating in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $9.38.
Shares of Insys Therapeutics (NASDAQ:INSY) opened at $5.18 on Friday. Insys Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.02.
TRADEMARK VIOLATION NOTICE: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/15/insys-therapeutics-insy-hold-rating-reiterated-at-oppenheimer-holdings-inc.html.
Several hedge funds have recently bought and sold shares of INSY. Wells Fargo & Company MN raised its holdings in shares of Insys Therapeutics by 30.3% in the 1st quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock valued at $289,000 after buying an additional 6,407 shares during the period. UBS Asset Management Americas Inc. acquired a new position in Insys Therapeutics during the 1st quarter worth $172,000. Parametric Portfolio Associates LLC grew its stake in Insys Therapeutics by 34.5% during the 1st quarter. Parametric Portfolio Associates LLC now owns 25,712 shares of the specialty pharmaceutical company’s stock worth $270,000 after purchasing an additional 6,600 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Insys Therapeutics by 37.9% during the 1st quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock worth $480,000 after purchasing an additional 12,561 shares in the last quarter. Finally, American International Group Inc. grew its stake in Insys Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 953 shares in the last quarter. Hedge funds and other institutional investors own 25.23% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.